Market Research Report
Renal Diseases Drug Development Pipeline Review, 2018
|Published by||GlobalData||Product code||766013|
|Published||Content info||154 Pages
Delivery time: 1-2 business days
|Renal Diseases Drug Development Pipeline Review, 2018|
|Published: December 19, 2018||Content info: 154 Pages||
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.
Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.
Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.
This report "Renal Diseases Drug Development Pipeline Review, 2018"provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.